Table 1.
Main outcomes of SGLT2i trials as summarized by SMART-C investigators [4]. Outcomes shown include kidney disease progression (sustained eGFR decrease ≥50% or < 15 mL/min/1.73 m2, end-stage kidney disease or death from kidney failure), acute kidney injury (MedDRA Preferred Term for AKI) and the combined endpoint of cardiovascular death and hospitalization for heart failure.
| Randomized Controlled Trial |
Kidney Disease Progression (RR [95%CI]) |
Acute Kidney Injury (RR [95%CI]) |
CV Death and HF Hospitalization (RR [95%CI]) |
|---|---|---|---|
| Diabetic Patients | |||
| EMPA-REG OUTCOME | 0.51 [0.35–0.76] | 0.41 [0.27–0.63] | 0.66 [0.55–0.79] |
| CANVAS | 0.61 [0.45–0.83] | 0.66 [0.39–1.11] | 0.78 [0.67–0.91] |
| DECLARE-TIMI 58 | 0.55 [0.39–0.76] | 0.69 [0.55–0.87] | 0.83 [0.73–0.95] |
| SCORED | 0.71 [0.46–1.08] | 1.04 [0.81–1.35] | 0.77 [0.66–0.91] |
| VERTIS CV | 0.76 [0.49–1.19] | 0.95 [0.57–1.59] | 0.88 [0.75–1.03] |
| DAPA-HF | 0.73 [0.39–1.34] | 0.79 [0.50–1.25] | 0.75 [0.63–0.90] |
| EMPEROR-Reduced | 0.52 [0.26–1.03] | 0.77 [0.46–1.28] | 0.72 [0.60–0.87] |
| EMPEROR-Preserved | 0.82 [0.53–1.27] | 0.69 [0.50–0.97] | 0.79 [0.67–0.94] |
| DELIVER | 0.87 [0.54–1.39] | 1.13 [0.68–1.63] | 0.80 [0.68–0.93] |
| SOLOIST-WHF | - | 0.94 [0.55–1.59] | 0.71 [0.56–0.89] |
| CREDENCE | 0.64 [0.52–0.79] | 0.85 [0.64–1.13] | 0.69 [0.57–0.83] |
| DAPA-CKD | 0.57 [0.45–0.73] | 0.66 [0.46–0.96] | 0.70 [0.53–0.92] |
| EMPA-KIDNEY | 0.55 [0.44–0.71] | 0.88 [0.64–1.20] | 0.78 [0.60–1.03] |
| Non-Diabetic Patients | |||
| DAPA-HF | 0.67 [0.30–1.49] | 0.60 [0.34–1.08] | 0.73 [0.60–0.89] |
| EMPEROR-Reduced | 0.50 [0.17–1.48] | 0.56 [0.32–0.98] | 0.78 [0.64–0.97] |
| EMPEROR-Preserved | 0.68 [0.33–1.40] | 0.80 [0.52–1.23] | 0.78 [0.64–0.95] |
| DELIVER | 1.01 [0.51–1.97] | 0.64 [0.41–1.02] | 0.82 [0.68–0.99] |
| DAPA-CKD | 0.51 [0.34–0.75] | 0.75 [0.39–1.43] | 0.79 [0.40–1.55] |
| EMPA-KIDNEY | 0.74 [0.59–0.95] | 0.63 [0.41–0.97] | 1.04 [0.65–1.67] |